Posted: Aug 8, 2016
Dr. Mark Gilbert, Chief, Neuro-Oncology Branch, describes an ambitious new clinical trial that, for the first time, will study the long-term progression of brain and spine cancers. The 10,000 patient trial is the largest of its kind and will follow patients throughout the course of their disease. In addition to identifying optimal treatments for common brain and spine cancers, the study focuses on treatment discovery for rare, overlooked cancers.
Posted: Jul 27, 2016
Posted: Jul 11, 2016
Dr. Ravi Madan, Clinical Director of the Genitourinary Malignancies Branch, is conducting a clinical trial for men who have metastatic prostate cancer but have not yet been treated with chemotherapy, abiraterone or enzalutamide.
New clinical trial combines LMB-100 with nab-paclitaxel for metastatic or locally advanced pancreatic cancer
Posted: Jul 8, 2016
Christine Alewine, Lasker Scholar, in the Laboratory of Molecular Biology is conducting a clinical study for patients with pancreatic cancer using a new immunotoxin drug, called LMB-100. It is a targeted immunotherapy that delivers a toxin to cancer cells that make a protein called mesothelin that is made by most pancreatic cancers.
Posted: Jun 8, 2016
The HIV and AIDS Malignancy Branch is collaborating with the Cancer Immunotherapy Trials Network to conduct a phase I clinical trial of pembrolizumab (Keytruda®) in HIV-positive patients with a variety of recurrent or refractory cancers.